BR112022013837A2 - Nanopartículas lipídicas - Google Patents
Nanopartículas lipídicasInfo
- Publication number
- BR112022013837A2 BR112022013837A2 BR112022013837A BR112022013837A BR112022013837A2 BR 112022013837 A2 BR112022013837 A2 BR 112022013837A2 BR 112022013837 A BR112022013837 A BR 112022013837A BR 112022013837 A BR112022013837 A BR 112022013837A BR 112022013837 A2 BR112022013837 A2 BR 112022013837A2
- Authority
- BR
- Brazil
- Prior art keywords
- lipid nanoparticles
- lnp
- lipid
- vaccines
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20152995 | 2020-01-21 | ||
| EP20152938 | 2020-01-21 | ||
| EP20179434 | 2020-06-11 | ||
| PCT/EP2021/051290 WO2021148511A1 (en) | 2020-01-21 | 2021-01-21 | Lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013837A2 true BR112022013837A2 (pt) | 2022-09-13 |
Family
ID=74215945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013837A BR112022013837A2 (pt) | 2020-01-21 | 2021-01-21 | Nanopartículas lipídicas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230067722A1 (https=) |
| EP (1) | EP4093373A1 (https=) |
| JP (1) | JP2023517275A (https=) |
| KR (1) | KR20230002300A (https=) |
| CN (1) | CN115697298A (https=) |
| AU (1) | AU2021211894A1 (https=) |
| BR (1) | BR112022013837A2 (https=) |
| CA (1) | CA3168696A1 (https=) |
| IL (1) | IL294624A (https=) |
| MX (1) | MX2022009018A (https=) |
| TW (1) | TW202139975A (https=) |
| WO (1) | WO2021148511A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020182993A1 (en) * | 2019-03-13 | 2020-09-17 | Etherna Immunotherapies Nv | Mrna vaccine |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| EP4346901A4 (en) * | 2021-06-01 | 2025-04-23 | The University of British Columbia | MRNA DELIVERY USING LIPID NANOPARTICLES |
| CA3238764A1 (en) * | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| CN114716355B (zh) * | 2022-04-02 | 2023-09-05 | 华南理工大学 | 一种脂质化合物、包含其的组合物及应用 |
| CN115887674B (zh) * | 2022-04-29 | 2023-08-25 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| CN115414476B (zh) * | 2022-08-15 | 2023-07-14 | 珠海暨创硒源纳米科技有限公司 | 一种改性氧化镁、含镁纳米颗粒水溶液及其制备方法与在制备佐剂中的应用 |
| WO2024064206A1 (en) * | 2022-09-20 | 2024-03-28 | Emory University | Lipid nanoparticles comprising nucleic acids encoding therapeutic genes and uses in medical methods |
| CN116763756A (zh) * | 2022-10-11 | 2023-09-19 | 中国科学院化学研究所 | 一种脂质纳米颗粒及其制备方法和应用 |
| JP7813825B2 (ja) * | 2023-02-07 | 2026-02-13 | 株式会社微生物化学研究所 | ワクチン |
| CN115998714B (zh) * | 2023-03-20 | 2023-06-30 | 威瑞生物科技(昆明)有限责任公司 | 一种脂质纳米颗粒、递送系统及递送系统的制备方法 |
| EP4442256A1 (en) | 2023-04-04 | 2024-10-09 | Københavns Universitet | Lipid nanoparticle compositions |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117159492A (zh) * | 2023-07-27 | 2023-12-05 | 广州制高点医药科技有限公司 | 一种含有唾液酸脂质衍生物的脂质纳米颗粒及其应用 |
| CN120359024A (zh) | 2023-10-12 | 2025-07-22 | 科百博生物股份有限公司 | 脂质纳米颗粒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110305769A1 (en) * | 2008-11-17 | 2011-12-15 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
| EP3243504A1 (en) * | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| KR101766408B1 (ko) * | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| ES2795110T3 (es) * | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| AU2014340149B2 (en) * | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| HUE058792T2 (hu) | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| EP3247398A4 (en) * | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| US11458106B2 (en) * | 2016-05-09 | 2022-10-04 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| WO2017218704A1 (en) * | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN109563511A (zh) * | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| WO2018175783A1 (en) * | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
| EP3733647B1 (en) * | 2017-12-27 | 2022-06-15 | Eisai R&D Management Co., Ltd. | Cationic lipid |
| CA3088485A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
-
2021
- 2021-01-21 EP EP21701492.7A patent/EP4093373A1/en active Pending
- 2021-01-21 BR BR112022013837A patent/BR112022013837A2/pt unknown
- 2021-01-21 IL IL294624A patent/IL294624A/en unknown
- 2021-01-21 TW TW110102316A patent/TW202139975A/zh unknown
- 2021-01-21 US US17/794,087 patent/US20230067722A1/en active Pending
- 2021-01-21 JP JP2022544069A patent/JP2023517275A/ja active Pending
- 2021-01-21 CA CA3168696A patent/CA3168696A1/en active Pending
- 2021-01-21 CN CN202180010449.4A patent/CN115697298A/zh active Pending
- 2021-01-21 AU AU2021211894A patent/AU2021211894A1/en active Pending
- 2021-01-21 KR KR1020227028916A patent/KR20230002300A/ko active Pending
- 2021-01-21 MX MX2022009018A patent/MX2022009018A/es unknown
- 2021-01-21 WO PCT/EP2021/051290 patent/WO2021148511A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4093373A1 (en) | 2022-11-30 |
| MX2022009018A (es) | 2022-08-11 |
| AU2021211894A1 (en) | 2022-09-01 |
| US20230067722A1 (en) | 2023-03-02 |
| TW202139975A (zh) | 2021-11-01 |
| WO2021148511A1 (en) | 2021-07-29 |
| JP2023517275A (ja) | 2023-04-25 |
| CA3168696A1 (en) | 2021-07-29 |
| KR20230002300A (ko) | 2023-01-05 |
| IL294624A (en) | 2022-09-01 |
| CN115697298A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013837A2 (pt) | Nanopartículas lipídicas | |
| Nishikawa et al. | Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery | |
| ZA202300131B (en) | Lipid nanoparticles | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| JP2023075165A (ja) | 核酸生成及び送達のための方法及び製品 | |
| MX2024009845A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| BR112022019124A2 (pt) | Composições e métodos para liberação de rna | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| MX2020010941A (es) | Moleculas y composiciones novedosas de arn de vsr para vacunacion. | |
| FI3688162T3 (fi) | Formulaatioita | |
| CL2018002825A1 (es) | Vacuna contra vrs | |
| MX2012000424A (es) | L-asparaginasa pegilada. | |
| EP4309739A3 (en) | Core/shell structure platform for immunotherapy | |
| NZ543467A (en) | The severe acute respiratory syndrome coronavirus | |
| BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
| WO2008052770A3 (en) | (base-)modified rna for increasing the expression of a protein | |
| BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
| BR112013002298A2 (pt) | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. | |
| BRPI0618857A8 (pt) | Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| UY35250A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos. | |
| BR112018074941A2 (pt) | combinações farmacêuticas | |
| BR112023003373A2 (pt) | Formulações estáveis que compreendem anticorpo biespecífico egfr/c-met | |
| MX2023000663A (es) | Constructos inmunogenicos, composiciones, y metodos para inducir la respuesta inmunitaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |